Palivizumab prophylaxis safe for second RSV season

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1376, 2003-01, pp. : 16-16

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Palivizumab poor performer for prevention of RSV

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 623, 2011-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Palivizumab for RSV prevention in high-risk children

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 520, 2007-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Palivizumab for RSV prevention in high-risk children

Inpharma, Vol. 1, Iss. 1573, 2007-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Evaluation of the Safety of Palivizumab in the Second Season of Exposure in Young Children at Risk for Severe Respiratory Syncytial Virus Infection

By Lacaze-Masmonteil T.

Drug Safety, Vol. 26, Iss. 4, 2003-01 ,pp. : 283-291

Adis International

Access to resources Recommend Favorite

Debating RSV prophylaxis in preterm infants

Inpharma, Vol. 1, Iss. 1266, 2000-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite